Lerkamen ACE 10/20, 28 tablets — Made in Germany — Free Delivery

Brand: Berlin-Chemie
Product Code: Lerkamen ACE 10/20
Availability: In Stock

$25.34

Description

Product description

Lerkamen® ACE10/10:

treatment of essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy with lercanidipine hydrochloride at a dose of 10 mg. It is not necessary to start treatment of arterial hypertension immediately with the combined preparation Lerkamen® ACE 10/10.

Lerkamen® ACE10/20:

treatment of essential hypertension in patients whose blood pressure is not adequately controlled with enalapril maleate monotherapy at a dose of 20 mg. It is not necessary to start treatment of arterial hypertension immediately with the combination preparation Lerkamen® ACE 10/20.

Compound

active ingredients: lercanidipine, enalapril;

Lerkamen® ACE 10/10 1 coated tablet contains lercanidipine hydrochloride 10 mg, equivalent to lercanidipine 9.44 mg and enalapril maleate 10 mg, equivalent to enalapril 7.64 mg;

Lerkamen® ACE 10/20 1 coated tablet contains lercanidipine hydrochloride 10 mg, equivalent to lercanidipine 9.44 mg and enalapril maleate 20 mg, equivalent to enalapril 15.29 mg;

Excipients:

lactose, microcrystalline cellulose, sodium starch (type A), povidone, sodium bicarbonate, magnesium stearate;
tablet shell Lerkamen® ACE 10/10: Opadry 02F29056 (hypromellose, titanium dioxide (E 171), talc, polyethylene glycol);
tablet shell Lerkamen® ACE 10/20: Opadry 02F22330 (hypromellose, titanium dioxide (E 171), talc, polyethylene glycol, quinoline yellow (E 104), iron oxide yellow (E172)).

Contraindications

Hypersensitivity to the active ingredients of the drug, any ACE inhibitor or calcium channel blockers of the dihydropyridine series, as well as to any of the excipients (see Section "Composition").

A history of angioedema as a result of prior treatment with an ACE inhibitor.

Hereditary or idiopathic angioedema.

Pregnancy or pregnancy planning (see sections "Peculiarities of use" and "Use during pregnancy or lactation").

The simultaneous use of the preparation Lerkamen® ACE and drugs containing aliskiren is contraindicated in patients with diabetes mellitus or impaired renal function (GFR <60 ml / min / 1.73 m2) (see Sections "Interaction with other drugs and other forms of interaction" and "Pharmacological").

Obstruction of the outflow of blood from the left ventricle, including aortic stenosis.

Congestive heart failure that has not been treated.

Unstable angina.

Within one month after myocardial infarction.

Severe renal failure (creatinine clearance <30 ml / min), including in patients on hemodialysis.

Severe liver failure.

Simultaneous use with:

potent inhibitors of CYP3A4 (see Section "Interaction with other medicinal products and other forms of interaction");
cyclosporine (see Section "Interaction with other medicinal products and other forms of interaction");
grapefruit juice (see Section "Interaction with other medicinal products and other types of interactions").

Mode of application

Precautions for taking or handling this preparation:

the preparation should preferably be taken in the morning, at least 15 minutes before breakfast;
this preparation should not be taken with grapefruit juice (see Sections "Interaction with other medicinal products and other forms of interaction" and "Contraindications").

Application features

pregnant

Contraindicated.

Children

The use of the preparation Lerkamen® ACE in children for the treatment of arterial hypertension is not indicated.

Drivers

Lerkamen® ACE has little effect on the ability to drive vehicles and other mechanisms. However, you should be careful, as dizziness, asthenia, fatigue, and in rare cases, drowsiness may occur (see section "Adverse reactions").

Overdose

Several cases of intentional overdose requiring hospitalization have been reported in post-marketing experience with enalapril/lercanidipine at doses of 100 to 1000 mg of each substance. Reported symptoms (decreased systolic blood pressure, bradycardia, restlessness, drowsiness, and flank pain) may have resulted from the concomitant use of other preparations at high doses (eg, β-blockers).

Side effects

Adverse reactions that most often occur during treatment with Lerkamen® ACE are cough (4.03%), dizziness (1.67%) and headache (1.67%).

Interaction

The antihypertensive effect of the preparation Lerkamen® ACE can be enhanced by other preparations that lower blood pressure, such as diuretics, β-blockers, α-blockers and other substances.

In addition, the following interactions are observed with each of the active ingredients of this preparation.

You should refrain from drinking alcohol due to the fact that it can enhance the vasodilating effect of antihypertensive preparations (see section "Peculiarities of use").

Storage conditions

Store at a temperature not exceeding 25°C. To protect from light and moisture, store the preparation in its original packaging. Keep out of the reach of children.

Shelf life - 2 years.

0 reviews

There are no reviews for this product.